Atopic Dermatitis Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DMPH79 | Last Updated On: Jun 09 2022 | Available Formats

> Global Atopic Dermatitis Market Expected to reach a high CAGR of 11% during the forecast period 2022-2029: DataM Intelligence.

Global Atopic Dermatitis Treatment Market is segmented By Disease Severity (Mild, Moderate, Severe), By Treatment Type (Corticosteroids, Antihistamines, Calcineurin Inhibitors, Immunomodulators, Biologic Therapy, PDE-4 Inhibitor), By Distribution Channel (Hospitals, Dermatology Clinics, Retail Pharmacy, Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2022-2029

 

Market Overview

The Global Atopic Dermatitis Market is expected to grow at a CAGR of  11% during the forecasting period (2022-2029).

  • Atopic Dermatitis is a chronic inflammatory disease of the skin and is highly prevalent in children with ~85% of cases present by 5 years of age.

  • It is characterized by flare-ups of itch, red inflamed rash, and excessive dryness or scaling of the skin. Globally, AD affects 15-20% of children and 1-3% of adults. The global Atopic Dermatitis market size is estimated at USD 4.8 billion, growing at an annual growth rate of 4% over the forecast period.

Market Growth

  • The large and growing patient population with atopic dermatitis and eczema represents an attractive revenue potential for companies. Some of the major growth drivers for the market include the launch of biologics for the treatment of moderate to severe disease, increase in uptake of topical calcineurin inhibitors within the emerging markets, and continued uptake of systemic therapies.

  • However, the high cost of biologic therapy, uptake of generic topical drugs, and pediatric population being the largest patient segment will act as a deterrent to market growth.

  • A significant shift in the treatment paradigm for AD is expected over the next few years with the launch of biologics and novel small molecules.

  • Novel therapies are likely to generate high demand from patients with moderate to severe atopic dermatitis since an estimated 19% of patients do not respond to currently available treatment regimens. Novel therapeutic target: dupilumab is touted as a potential breakthrough therapy for moderate to severe disease.

  • It was approved by the Food and Drug Administration (FDA) in March 2017 and is estimated to achieve peak annual sales of USD 4 billion.

Market Segmentation

  • The global Atopic Dermatitis market report segments the market by disease severity, treatment type, mode of administration, by distribution channel, and lastly by region.

  •  Based on different clinical signs and intensity of symptoms, the AD market is classified into three types – mild, moderate, and severe. This categorization helps healthcare providers determine the best course of treatment. Segmentation based on treatment types used includes drug classes such as corticosteroids, antihistamines, calcineurin inhibitors, Immunomodulators, biologic therapy, a PDE-4 inhibitor, antibiotics, moisturizers/emollients, and Off-label therapies.

  • Topical corticosteroids are the most widely used pharmacologic treatment for AD and are often recommended as first-line therapy for the moderate-severe disease.

  • Next are calcineurin inhibitors that are used as second-line treatment and are the only non-steroidal pharmacologic therapy approved for atopic dermatitis. Lastly, the market is classified based on distribution channels into Hospitals, Clinics, Retail Pharmacies, and Online Pharmacy.

  • Geographically, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.

  • North America is the largest market for Atopic Dermatitis in terms of global AD market share owing to a large and growing patient population with atopic dermatitis and eczema. Around 17.8 million people have some form of atopic dermatitis. Thus, the US represents a huge target market for AD. The US atopic dermatitis market is valued at USD 1.7 billion, growing at an annual rate of 4%.

Features of this report

The report also profiles the following companies in the atopic dermatitis market – Pfizer Inc., Mylan       N.V, LEO Pharma Inc., Novartis, Sanofi, and Valeant. Anacor, a biotech company making non-steroidal topical PDE4 inhibitor crisaborole, was acquired by Pfizer in 2016.

Key takeaways from this report

The professional purchasing the DMI report on the global AD market will be able to do the following:

  • Visualize the composition of the Atopic Dermatitis market across each indication, in terms of type and treatment options, highlighting the key commercial assets and players.

  • Identify commercial opportunities in the Atopic Dermatitis market by analyzing trends and co-development deals.

  • Excel data sheet with thousands of data points of the Atopic Dermatitis market-level 4/5 segmentation.

  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

  • Product mapping in excel for the key Atopic Dermatitis of all major market players

Trending Topics

Actinic Keratosis Treatment Market

Rheumatoid Arthritis Drugs Market

Carbon Fiber Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest